Allergan’s RetroSense Buy Marks Move Into Gene Therapy
The company agreed to pay $60m upfront to buy privately-held RetroSense, the developer of a novel gene therapy in Phase I/II clinical testing for retinitis pigmentosa. The investment in early R&D helps Allergan catch up with other eye care research.
You may also be interested in...
Finance Watch: Mysterious Gossamer Raises $100m As VC Deals Surge Ahead of J.P. Morgan
Gossamer Bio, led by former Receptos CEO Faheem Hasnain and CMO Sheila Gujrathi, revealed $100m in seed and Series A funding during a week in which 17 companies revealed VC rounds totaling $891.2m, giving them good news to discuss during the J.P. Morgan Healthcare conference.
Editas Deal Opens Allergan's Eyes To CRISPR Opportunities
Editas' stock shot up 11% by mid-morning on March 14, after the gene therapy company announced a deal with Allergan worth $90m up front for "cool" CRISPR programs in ocular indications. However, the lead therapy included in the deal offers potentially limited profitability in a small orphan space.
‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study
Allergan will pay $200m to exercise its option to buy Motus Therapeutics (formerly Rhythm Health) after what the pharma described as a successful Phase IIb study for relamorelin in diabetic gastroparesis.